Additionally, survival curve analysis using data from The Cancer Genome Atlas (TCGA) demonstrated that high MARCH2 expression was associated with reduced survival rates in patients with clear cell renal cell carcinoma and colon cancers (Fig. 7B). Here, MARCHF2 is linked to malignant colon neoplasm.